{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:16:39Z","timestamp":1781295399209,"version":"3.54.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clinicians are faced with an increasingly difficult choice regarding the optimal bronchodilator for patients with chronic obstructive pulmonary disease (COPD) given the number of new treatments. The objective of this study is to evaluate the comparative efficacy of indacaterol 75\/150\/300\u00a0\u03bcg once daily (OD), glycopyrronium bromide 50\u00a0\u03bcg OD, tiotropium bromide 18\u00a0\u03bcg\/5\u00a0\u03bcg OD, salmeterol 50\u00a0\u03bcg twice daily (BID), formoterol 12\u00a0\u03bcg BID, and placebo for moderate to severe COPD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty randomized controlled trials were combined in a Bayesian network meta-analysis. Outcomes of interest were trough and post-dose forced expiratory volume in 1\u00a0second (FEV<jats:sub>1<\/jats:sub>), St. George\u2019s Respiratory Questionnaire (SGRQ) score and responders (\u22654 points), and Transition Dyspnea Index (TDI) score and responders (\u22651 point) at 6\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Indacaterol was associated with a higher trough FEV<jats:sub>1<\/jats:sub>than other active treatments (difference for indacaterol 150\u00a0\u03bcg and 300\u00a0\u03bcg versus placebo: 152\u00a0mL (95% credible interval (CrI): 126, 179); 160\u00a0mL (95% CrI: 133, 187)) and the greatest improvement in SGRQ score (difference for indacaterol 150\u00a0\u03bcg and 300\u00a0\u03bcg versus placebo: -3.9 (95% CrI -5.2, -2.6); -3.6 (95% CrI -4.8, -2.3)). Glycopyrronium and tiotropium 18\u00a0\u03bcg resulted in the next best estimates for both outcomes with minor differences (difference for glycopyrronium versus tiotropium for trough FEV<jats:sub>1<\/jats:sub>and SGRQ: 18\u00a0mL (95% CrI: -16, 51); -0.55 (95% CrI: -2.04, 0.92).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In terms of trough FEV<jats:sub>1<\/jats:sub>and SGRQ score indacaterol, glycopyrronium, and tiotropium are expected to be the most effective bronchodilators.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1465-9921-14-100","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T07:14:27Z","timestamp":1381130067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Shannon","family":"Cope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorana","family":"Capkun-Niggli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,7]]},"reference":[{"key":"1423_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2013Feb13.pdf,"},{"key":"1423_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1081\/COPD-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW: St. George\u2019s Respiratory questionnaire: MCID. COPD. 2005, 2: 75-79. 10.1081\/COPD-200050513.","journal-title":"COPD"},{"key":"1423_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","volume":"21","author":"TJ Witek Jr","year":"2003","unstructured":"Witek TJ, Mahler DA: Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003, 21: 267-272. 10.1183\/09031936.03.00068503a.","journal-title":"Eur Respir J"},{"key":"1423_CR4","volume-title":"Novartis data on file","author":"R Firth","year":"2010","unstructured":"Firth R, Henley M, Kramer B, Lassen C, Yang W, Owen R: Full clinical study report for study number QAB149B2333: a phase III, 26-week multi-center randomized double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (150 and 300 \u03bcg od) in patients with chronic obstructive pulmonary disease. Novartis data on file. 2010"},{"key":"1423_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1183\/09031936.00191810","volume":"38","author":"R Buhl","year":"2011","unstructured":"Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B: Blinded 12- week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011, 38: 797-803. 10.1183\/09031936.00191810.","journal-title":"Eur Respir J"},{"key":"1423_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/thx.2009.125435","volume":"65","author":"R Dahl","year":"2010","unstructured":"Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B: L Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010, 65: 473-479. 10.1136\/thx.2009.125435.","journal-title":"Thorax"},{"key":"1423_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","volume":"182","author":"JF Donohue","year":"2010","unstructured":"Donohue JF, Fogarty C, L\u00f6tvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010, 182: 155-162. 10.1164\/rccm.200910-1500OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1423_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1465-9921-12-156","volume":"12","author":"A D\u2019Urzo","year":"2011","unstructured":"D\u2019Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate to severe COPD: the GLOW1 trial. Respir Res. 2011, 12: 156-10.1186\/1465-9921-12-156.","journal-title":"Respir Res"},{"key":"1423_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2466-10-11","volume":"10","author":"G Feldman","year":"2010","unstructured":"Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B: Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010, 10: 1-9. 10.1186\/1471-2466-10-1.","journal-title":"BMC Pulm Med"},{"key":"1423_CR10","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.clinthera.2011.11.009","volume":"33","author":"EM Kerwin","year":"2011","unstructured":"Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B: Efficacy and tolerability of indacaterol 75 \u03bcg once daily in patients aged \u226540 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011, 33: 1974-1984. 10.1016\/j.clinthera.2011.11.009.","journal-title":"Clin Ther"},{"key":"1423_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1183\/09031936.00040712","volume":"40","author":"E Kerwin","year":"2012","unstructured":"Kerwin E, H\u00e9bert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J. 2012, 40: 1106-1114. 10.1183\/09031936.00040712.","journal-title":"Eur Respir J"},{"key":"1423_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1440-1843.2011.02107.x","volume":"17","author":"M Kinoshita","year":"2012","unstructured":"Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y: Efficacy and safety of indacaterol 150 and 300 \u03bcg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology. 2012, 17: 379-389. 10.1111\/j.1440-1843.2011.02107.x.","journal-title":"Respirology"},{"key":"1423_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.rmed.2011.02.008","volume":"105","author":"S Korn","year":"2011","unstructured":"Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C: Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study. Respir Med. 2011, 105: 719-726. 10.1016\/j.rmed.2011.02.008.","journal-title":"Respir Med"},{"key":"1423_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1183\/09031936.00045810","volume":"37","author":"O Kornmann","year":"2011","unstructured":"Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B: Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011, 37: 273-279. 10.1183\/09031936.00045810.","journal-title":"Eur Respir J"},{"key":"1423_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005, 331: 897-900. 10.1136\/bmj.331.7521.897.","journal-title":"BMJ"},{"key":"1423_CR16","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004, 23: 3105-3124. 10.1002\/sim.1875.","journal-title":"Stat Med"},{"key":"1423_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","volume":"11","author":"J Jansen","year":"2008","unstructured":"Jansen J, Crawford B, Bergman G, Stam W: Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008, 11: 956-964. 10.1111\/j.1524-4733.2008.00347.x.","journal-title":"Value Health"},{"key":"1423_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC: Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011, 14: 417-428. 10.1016\/j.jval.2011.04.002.","journal-title":"Value Health"},{"key":"1423_CR19","volume-title":"Bayesian approaches to clinical trials and health care evaluation","author":"D Spiegelhalter","year":"2004","unstructured":"Spiegelhalter D, Abrams K, Myles J: Bayesian approaches to clinical trials and health care evaluation. 2004, Chichester, UK: Wiley"},{"key":"1423_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A: Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 2011, 14: 429-437. 10.1016\/j.jval.2011.01.011.","journal-title":"Value Health"},{"issue":"5","key":"1423_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013, 33 (5): 607-17. 10.1177\/0272989X12458724.","journal-title":"Med Decis Making"},{"key":"1423_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/sim.3594","volume":"28","author":"NJ Cooper","year":"2009","unstructured":"Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ: Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009, 28: 1861-1881. 10.1002\/sim.3594.","journal-title":"Stat Med"},{"key":"1423_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1018598421607","volume":"7","author":"AP Dempster","year":"1997","unstructured":"Dempster AP: The direct use of likelihood for significance testing. Stat Comput. 1997, 7: 247-252. 10.1023\/A:1018598421607.","journal-title":"Stat Comput"},{"key":"1423_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N, Spiegelhalter D: WinBUGS \u2013 a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000, 10: 325-337. 10.1023\/A:1008929526011.","journal-title":"Stat Comput"},{"key":"1423_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analyses: an overview and tutorial. J Clin Epidemiol. 2011, 64: 163-171. 10.1016\/j.jclinepi.2010.03.016.","journal-title":"J Clin Epidemiol"},{"key":"1423_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.rmed.2010.06.004","volume":"104","author":"ED Bateman","year":"2010","unstructured":"Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D, Pavia D, Zhong NS: A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010, 104: 1460-1472. 10.1016\/j.rmed.2010.06.004.","journal-title":"Respir Med"},{"key":"1423_CR27","first-page":"197","volume":"5","author":"E Bateman","year":"2010","unstructured":"Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, Blatchford J, Pavia D, Hodder R: Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis. 2010, 5: 197-208.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1423_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.pupt.2005.02.013","volume":"18","author":"DD Briggs Jr","year":"2005","unstructured":"Briggs DD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C: Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005, 18: 397-404. 10.1016\/j.pupt.2005.02.013.","journal-title":"Pulm Pharmacol Ther"},{"key":"1423_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/thorax.58.5.399","volume":"58","author":"V Brusasco","year":"2003","unstructured":"Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003, 58: 399-404. 10.1136\/thorax.58.5.399.","journal-title":"Thorax"},{"key":"1423_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","volume":"361","author":"P Calverley","year":"2003","unstructured":"Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003, 361: 449-456. 10.1016\/S0140-6736(03)12459-2.","journal-title":"Lancet"},{"key":"1423_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med. 2007, 356: 775-789. 10.1056\/NEJMoa063070.","journal-title":"N Eng J Med"},{"key":"1423_CR32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1378\/chest.118.5.1294","volume":"118","author":"R Casaburi","year":"2000","unstructured":"Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek TJ: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicentre trial. Chest. 2000, 118: 1294-1302. 10.1378\/chest.118.5.1294.","journal-title":"Chest"},{"key":"1423_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1183\/09031936.02.00269802","volume":"19","author":"R Casaburi","year":"2002","unstructured":"Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002, 19: 217-224. 10.1183\/09031936.02.00269802.","journal-title":"Eur Respir J"},{"issue":"Suppl A","key":"1423_CR34","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0954-6111(03)80013-6","volume":"97","author":"B Celli","year":"2003","unstructured":"Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M: Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale BCSS. Respir Med. 2003, 97 (Suppl A): S35-S43.","journal-title":"Respir Med"},{"key":"1423_CR35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1155\/2007\/192961","volume":"14","author":"CK Chan","year":"2007","unstructured":"Chan CK, Maltais F, Sigouin C, Haddon JM, Ford GT: A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J. 2007, 14: 465-472.","journal-title":"Can Respir J"},{"key":"1423_CR36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1155\/2002\/493296","volume":"9","author":"KR Chapman","year":"2002","unstructured":"Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS, Kuipers AF: The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: A randomized, placebo controlled trial. Chronic obstructive pulmonary disease. Can Respir J. 2002, 9: 178-185.","journal-title":"Can Respir J"},{"key":"1423_CR37","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1592\/phco.2005.25.12.1708","volume":"25","author":"H Covelli","year":"2005","unstructured":"Covelli H, Bhattacharya S, Cassino C, Conoscenti C, Kesten S: Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy. 2005, 25: 1708-1718. 10.1592\/phco.2005.25.12.1708.","journal-title":"Pharmacotherapy"},{"key":"1423_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","volume":"164","author":"R Dahl","year":"2001","unstructured":"Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 164: 778-784. 10.1164\/ajrccm.164.5.2007006.","journal-title":"Am J Respir Crit Care Med"},{"key":"1423_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1378\/chest.122.1.47","volume":"122","author":"JF Donohue","year":"2002","unstructured":"Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten S, Towse L: A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002, 122: 47-55. 10.1378\/chest.122.1.47.","journal-title":"Chest"},{"key":"1423_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2007.10.007","volume":"102","author":"NJ Gross","year":"2008","unstructured":"Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K, Formoterol study group: Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008, 102: 189-197. 10.1016\/j.rmed.2007.10.007.","journal-title":"Respir Med"},{"key":"1423_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1378\/chest.124.3.834","volume":"124","author":"NA Hanania","year":"2003","unstructured":"Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T: The efficacy and safety of fluticasone propionate (250 mug)\/salmeterol (50 mug) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003, 124: 834-843. 10.1378\/chest.124.3.834.","journal-title":"Chest"},{"key":"1423_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1465-9921-12-55","volume":"12","author":"PW Jones","year":"2011","unstructured":"Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, Donohue J, Bateman ED, Gross NJ, Lamarca R, Caracta C, Garcia Gil E: Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011, 12: 55-10.1186\/1465-9921-12-55.","journal-title":"Respir Res"},{"key":"1423_CR43","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1164\/rccm.2112055","volume":"166","author":"DA Mahler","year":"2002","unstructured":"Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002, 166: 1084-1091. 10.1164\/rccm.2112055.","journal-title":"Am J Respir Crit Care Med"},{"key":"1423_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pupt.2007.04.003","volume":"21","author":"J Moita","year":"2008","unstructured":"Moita J, B\u00e1rbara C, Cardoso J, Costa R, Sousa M, Ruiz J, Santos ML: Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther. 2008, 21: 146-151. 10.1016\/j.pupt.2007.04.003.","journal-title":"Pulm Pharmacol Ther"},{"key":"1423_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-143-5-200509060-00007","volume":"143","author":"DE Niewoehner","year":"2005","unstructured":"Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, Cassino C, Kesten S: Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005, 143: 317-326. 10.7326\/0003-4819-143-5-200509060-00007.","journal-title":"Ann Intern Med"},{"key":"1423_CR46","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","volume":"121","author":"A Rossi","year":"2002","unstructured":"Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002, 121: 1058-1069. 10.1378\/chest.121.4.1058.","journal-title":"Chest"},{"key":"1423_CR47","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/thx.54.11.995","volume":"54","author":"M Rutten-van M\u00f6lken","year":"1999","unstructured":"Rutten-van M\u00f6lken M, Roos B, Van Noord JA: An empirical comparison of the St George\u2019s Respiratory Questionnaire SGRQ and the Chronic Respiratory Disease Questionnaire CRQ in a clinical trial setting. Thorax. 1999, 54: 995-1003. 10.1136\/thx.54.11.995.","journal-title":"Thorax"},{"key":"1423_CR48","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 1543-1554. 10.1056\/NEJMoa0805800.","journal-title":"N Engl J Med"},{"key":"1423_CR49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/COPD.S2463","volume":"3","author":"AB Tonnel","year":"2008","unstructured":"Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M: Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008, 3: 301-310.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1423_CR50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1159\/000089655","volume":"73","author":"C Verkindre","year":"2006","unstructured":"Verkindre C, Bart F, Aguilaniu B, Fortin F, Gu\u00e9rin JC, Le Merre C, Iacono P, Huchon G: The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006, 73: 420-427. 10.1159\/000089655.","journal-title":"Respiration"},{"key":"1423_CR51","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","volume":"102","author":"C Vogelmeier","year":"2008","unstructured":"Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J: Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008, 102: 1511-1520. 10.1016\/j.rmed.2008.07.020.","journal-title":"Respir Med"},{"key":"1423_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.rmed.2007.08.009","volume":"102","author":"T Voshaar","year":"2008","unstructured":"Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, Bateman E: A randomized study of tiotropium Respimat Soft Mist Inhaler vs. ipratropium pMDI in COPD. Respir Med. 2008, 102: 32-341. 10.1016\/j.rmed.2007.08.009.","journal-title":"Respir Med"},{"key":"1423_CR53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","volume":"10","author":"G Boyd","year":"1997","unstructured":"Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease COPD. Eur Respir J. 1997, 10: 815-821.","journal-title":"Eur Respir J"},{"key":"1423_CR54","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.pupt.2006.06.003","volume":"20","author":"SC Campbell","year":"2007","unstructured":"Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, Ziehmer BA: Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2007, 20: 571-579. 10.1016\/j.pupt.2006.06.003.","journal-title":"Pulm Pharmacol Ther"},{"key":"1423_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/15412550701815981","volume":"5","author":"GJ Criner","year":"2008","unstructured":"Criner GJ, Sharafkhaneh A, Player R, Conoscenti CS, Johnson P, Keyser MT, Cassino C: Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD. 2008, 5: 35-41. 10.1080\/15412550701815981.","journal-title":"COPD"},{"issue":"3","key":"1423_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1183\/09031936.06.00062705","volume":"27","author":"D Dusser","year":"2006","unstructured":"Dusser D, Bravo ML, Iacono P: The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006, 27 (3): 547-555. 10.1183\/09031936.06.00062705.","journal-title":"Eur Respir J"},{"key":"1423_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1465-9921-8-45","volume":"8","author":"D Freeman","year":"2007","unstructured":"Freeman D, Lee A, Price D: Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. Respir Res. 2007, 8: 45-10.1186\/1465-9921-8-45. epub","journal-title":"Respir Res"},{"key":"1423_CR58","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","volume":"155","author":"PW Jones","year":"1997","unstructured":"Jones PW, Bosh TK: Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997, 155: 1283-1289. 10.1164\/ajrccm.155.4.9105068.","journal-title":"Am J Respir Crit Care Med"},{"key":"1423_CR59","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1378\/chest.130.3.647","volume":"130","author":"DE O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K: Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006, 130: 647-656. 10.1378\/chest.130.3.647.","journal-title":"Chest"},{"key":"1423_CR60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/09031936.00023907","volume":"30","author":"DJ Powrie","year":"2007","unstructured":"Powrie DJ, Wilkinson TM, Donaldson GC, Jones P, Scrine K, Viel K, Kesten S, Wedzicha JA: Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007, 30: 472-478. 10.1183\/09031936.00023907.","journal-title":"Eur Respir J"},{"key":"1423_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/thx.2004.033266","volume":"6","author":"RA Stockley","year":"2006","unstructured":"Stockley RA, Chopra N, Rice L: Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006, 6: 122-128.","journal-title":"Thorax"},{"key":"1423_CR62","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1034\/j.1399-3003.2000.15e11.x","volume":"15","author":"JA van Noord","year":"2000","unstructured":"van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000, 15: 878-885. 10.1034\/j.1399-3003.2000.15e11.x.","journal-title":"Eur Respir J"},{"key":"1423_CR63","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","volume":"364","author":"C Vogelmeier","year":"2011","unstructured":"Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van M\u00f6lken MP, Beeh KM, Rabe KF, Fabbri LM: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011, 364: 1093-1103. 10.1056\/NEJMoa1008378.","journal-title":"N Engl J Med"},{"key":"1423_CR64","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1592\/phco.29.8.891","volume":"29","author":"WL Baker","year":"2009","unstructured":"Baker WL, Baker EL, Coleman CI: Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009, 29: 891-905. 10.1592\/phco.29.8.891.","journal-title":"Pharmacotherapy"},{"key":"1423_CR65","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1183\/09031936.00099306","volume":"31","author":"M Cazzola","year":"2008","unstructured":"Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van M\u00f6lken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31: 416-469. 10.1183\/09031936.00099306.","journal-title":"Eur Respir J"},{"key":"1423_CR66","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2147\/COPD.S23816","volume":"6","author":"JF Donohue","year":"2011","unstructured":"Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B: Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011, 6: 477-492.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1423_CR67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","volume":"155","author":"A Qaseem","year":"2011","unstructured":"Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Sch\u00fcnemann H, Wedzicha W, MacDonald R, Shekelle P: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011, 155: 179-191. 10.7326\/0003-4819-155-3-201108020-00008.","journal-title":"Ann Intern Med"},{"key":"1423_CR68","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1465-9921-13-52","volume":"13","author":"K Beeh","year":"2012","unstructured":"Beeh K, Beier J, Donohue JF: Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res. 2012, 13: 52-10.1186\/1465-9921-13-52.","journal-title":"Respir Res"},{"key":"1423_CR69","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.rmed.2010.11.019","volume":"105","author":"F Maltais","year":"2011","unstructured":"Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C: Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011, 105: 580-587. 10.1016\/j.rmed.2010.11.019.","journal-title":"Respir Med"},{"key":"1423_CR70","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1183\/09031936.00225511","volume":"40","author":"PW Jones","year":"2012","unstructured":"Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Gil EG: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012, 40: 830-836. 10.1183\/09031936.00225511.","journal-title":"Eur Respir J"},{"key":"1423_CR71","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1741-7015-7-2","volume":"7","author":"MA Puhan","year":"2009","unstructured":"Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG: Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med. 2009, 7: 2-10.1186\/1741-7015-7-2.","journal-title":"BMC Med"},{"key":"1423_CR72","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/COPD.S18759","volume":"6","author":"S Cope","year":"2011","unstructured":"Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP: Comparative efficacy of indacaterol 150\u03bcg and 300\u03bcg versus fixed-dose combinations of formoterol\u2009+\u2009budesonide or salmeterol\u2009+\u2009fluticasone for the treatment of chronic obstructive pulmonary disease\u2013a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2011, 6: 329-344.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1423_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/COPD.S31526","volume":"7","author":"S Cope","year":"2012","unstructured":"Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP: Efficacy of indacaterol 75 \u03bcg versus fixed-dose combinations of formoterol\/ budesonide or salmeterol\/fluticasone for COPD \u2013 a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012, 7: 415-420.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1423_CR74","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jval.2012.01.009","volume":"15","author":"S Cope","year":"2012","unstructured":"Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP: Efficacy of Once-daily indacaterol relative to alternative bronchodilators in COPD: a patient level mixed treatment comparison. Value Health. 2012, 15: 524-533. 10.1016\/j.jval.2012.01.009.","journal-title":"Value Health"},{"key":"1423_CR75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2466-12-29","volume":"12","author":"S Cope","year":"2012","unstructured":"Cope S, Zhang J, Williams J, Jansen JP: Efficacy of once-daily indacaterol 75 \u03bcg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis. BMC Pulm Med. 2012, 12: 29-10.1186\/1471-2466-12-29.","journal-title":"BMC Pulm Med"},{"key":"1423_CR76","volume-title":"Cochrane Database Syst Rev","author":"J Chong","year":"2012","unstructured":"Chong J, Karner C, Poole P: Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012, 9: CD009157"},{"key":"1423_CR77","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1378\/chest.11-2252","volume":"142","author":"GJ Rodrigo","year":"2012","unstructured":"Rodrigo GJ, Neffen H: Comparison of indacaterol with tiotropium or twice-daily long-acting \u03b2 -agonists for stable COPD: a systematic review. Chest. 2012, 142: 1104-1110. 10.1378\/chest.11-2252.","journal-title":"Chest"},{"key":"1423_CR78","volume-title":"Cochrane Database Syst Rev","author":"C Karner","year":"2012","unstructured":"Karner C, Chong J, Poole P: Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012, 7: CD009285"},{"key":"1423_CR79","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/thx.2010.136077","volume":"65","author":"PM Calverley","year":"2010","unstructured":"Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J: Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010, 65: 719-725. 10.1136\/thx.2010.136077.","journal-title":"Thorax"},{"key":"1423_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1465-9921-11-56","volume":"11","author":"A Kliber","year":"2010","unstructured":"Kliber A, Lynd LD, Sin DD: The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res. 2010, 11: 56-10.1186\/1465-9921-11-56.","journal-title":"Respir Res"},{"key":"1423_CR81","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1378\/chest.07-1167","volume":"133","author":"GJ Rodrigo","year":"2008","unstructured":"Rodrigo GJ, Nannini LJ, Rodr\u00edguez-Roisin R: Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008, 133: 1079-1087. 10.1378\/chest.07-1167.","journal-title":"Chest"},{"key":"1423_CR82","doi-asserted-by":"publisher","first-page":"d3215","DOI":"10.1136\/bmj.d3215","volume":"342","author":"S Singh","year":"2011","unstructured":"Singh S, Loke YK, Enright PL, Furberg CD: Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011, 342: d3215-10.1136\/bmj.d3215.","journal-title":"BMJ"},{"key":"1423_CR83","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.rmed.2010.11.027","volume":"105","author":"H Worth","year":"2011","unstructured":"Worth H, Chung KF, Felser JM, Hu H, Rueegg P: Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011, 105: 571-579. 10.1016\/j.rmed.2010.11.027.","journal-title":"Respir Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-14-100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:39:18Z","timestamp":1688528358000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/1465-9921-14-100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,7]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1186\/1465-9921-14-100","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,7]]},"assertion":[{"value":"14 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"100"}}